Home › Research › Prevention and risk
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Kim HK, Biessels GJ, Yu MH, Hong N, Lee YH, Lee BW, et al.. Neurology, 2024-09-18
Topic: Brain proteins, microglia and lab models
Plain-language summary
Results From the 358,862 participants analyzed (mean [SD] age, 57.8 [9.6] years; 58.0% male), 6,837 incident dementia or PD events occurred. Regarding the individual endpoints, SGLT2i use was associated with reduced risks of AD (adjusted hazard ratio [aHR] 0.81, 95% CI 0.76-0.87), VaD (aHR 0.69, 95% CI 0.60-0.78), and PD (aHR 0.80, 95% CI 0.69-0.91) with a 6-month drug use lag period. In addition, use of SGLT2i was associated with a 21% lower risk of all-cause dementia (aHR 0.79, 95% CI 0.69-0.90) and a 22% lower risk of all-cause dementia and PD than use of other OADs (aHR 0.78, 95% CI 0.73-0.83). Sensitivity analysis further adjusting for bioclinical variables from health screening tests, including blood pressure, glucose, lipid profiles, and kidney function, yielded generally consistent results. Discussion In this nationwide population-based study, SGLT2i use significantly reduced the risks of neurodegenerative disorders in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 358,862 participants. In this nationwide population-based study of 358,862 people with type 2 diabetes, SGLT2 inhibitor use was associated with reduced risks of Alzheimer disease, vascular dementia, and Parkinson disease. Reported effect size: All-cause dementia aHR 0.79 (95% CI 0.69-0.90) for SGLT2 inhibitor vs other oral antidiabetic drugs.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kim, H. K., Biessels, G. J., Yu, M. H., Hong, N., Lee, Y. H., Lee, B. W., et al. (2024). SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. Neurology. https://doi.org/10.1212/WNL.0000000000209805
Vancouver
Kim HK, Biessels GJ, Yu MH, Hong N, Lee YH, Lee BW, et al. SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. Neurology. 2024. doi:10.1212/WNL.0000000000209805. PMID: 39292986.
BibTeX
@article{kim2024-39292986,
author = {Kim, H. K. and Biessels, G. J. and Yu, M. H. and Hong, N. and Lee, Y. H. and Lee, B. W. and others},
title = {{SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes}},
journal = {Neurology},
year = {2024},
doi = {10.1212/WNL.0000000000209805},
pmid = {39292986},
url = {https://doi.org/10.1212/WNL.0000000000209805}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results From the 358,862 participants analyzed (mean [SD] age, 57.8 [9.6] years; 58.0% male), 6,837 incident dementia or PD events occurred.
- Regarding the individual endpoints, SGLT2i use was associated with reduced risks of AD (adjusted hazard ratio [aHR] 0.81, 95% CI 0.76-0.87), VaD (aHR 0.69, 95% CI 0.60-0.78), and PD (aHR 0.80, 95% CI 0.69-0.91) with a 6-month drug use lag period.
- In addition, use of SGLT2i was associated with a 21% lower risk of all-cause dementia (aHR 0.79, 95% CI 0.69-0.90) and a 22% lower risk of all-cause dementia and PD than use of other OADs (aHR 0.78, 95% CI 0.73-0.83).
- Sensitivity analysis further adjusting for bioclinical variables from health screening tests, including blood pressure, glucose, lipid profiles, and kidney function, yielded generally consistent results.
- Discussion In this nationwide population-based study, SGLT2i use significantly reduced the risks of neurodegenerative disorders in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters.
Why it matters
In this nationwide population-based study of 358,862 people with type 2 diabetes, SGLT2 inhibitor use was associated with reduced risks of Alzheimer disease, vascular dementia, and Parkinson disease. It suggests these drugs may be linked to lower risk of neurodegenerative disorders, but the observational design cannot prove cause and effect or show a treatment for existing dementia.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort
- Participants358,862
- Effect sizeAll-cause dementia aHR 0.79 (95% CI 0.69-0.90) for SGLT2 inhibitor vs other oral antidiabetic drugs
- Evidence strengthModerate
Limitations
Observational with possible residual confounding by indication; relatively young cohort with short follow-up; Korean population.
How this study scored 70/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 69 of the 98 points we could judge it on, which is 70 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 358,862 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 63 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.8 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 17.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 3 / 4 | Cited 63 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Minyoung Lee: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Yonsei University: institution h-index 777 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39292986) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 69 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 69 of the 98 points we could judge it on is 70 out of 100. |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/WNL.0000000000209805
- PubMed: 39292986
- Original source →
- Free full text: dspace.library.uu.nl →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.